2α, 3α-EPITHIO-5α-ANDROSTAN-17β-OI IN TREATMENT OF CHRONIC MASTOPATHY

スポンサーリンク

概要

• 論文の詳細を見る

• The effect of sulfur containing epithioandrostanol (2α, 3α-epithio-5α-androstan-17β-ol) on mastopathy was discussed in the same manner as was done in the previous investigations. The drug recipients were divided into four groups: Group S-1 receiving 10mg, group S-2, 20mg of this agent, and group M-1 and group M-2, control groups, receiving 50mg, and 100mg of dromostanolone propionate respectively. The patients were assigned randomly to the groups by use of a table of random numbers. The drug was administered in a double blind fashion. From the clinical and side effects it was concluded that the dosage given to group S-1 (10mg of epithioandrostanol per week) was adequate in clinical application. An increase of the body weight of experimental subjects revealed that this agent had less anabolic activity.

• 社団法人 日本内分泌学会の論文

著者

• IZUO Masaru

  Department of Breast Surgery, Syorakudo Hospital

• FUJIMORI MASAO

  Department of Surgery, Gunma University School of Medicine

関連論文

• Outcome of Breast-Conserving Therapy in the Tokyo Women's Medical University Breast Cancer Society Experience
• Decision Making Using Postoperative CEA and CA 15-3 for Detection of Breast Cancer Recurrence
• 2α, 3α-EPITHIO-5α-ANDROSTAN-17β-OI IN TREATMENT OF CHRONIC MASTOPATHY
• STUDIES ON HORMONAL TREATMENT FOR MASTOPATHY, PARTICULARLY ITS DOSE-RESPONSE RELATIONSHIP

スポンサーリンク